Abstract 5519
Background
The elderly (above 65 years) have become the leading population of our society. Their multitude of healthcare chronic problems demands palliative care and therefore Palliative Care problems and needs (PCPN) assessment.
Methods
A quantitative study using structured questionnaires [PNPC, Mini – Mental State Examination (MMSE), demographic and clinical characteristics] was conducted through December 2018 – February 2019, at internal medicine wards of a public general hospital. Patients with MMSE<24, at the end of life and with recent surgery were excluded. A translated in Hellenic language short-form version of PCPN used assessing Palliative Care Problems and Need for Professional Care. The PCPN is a 33 items 3-point Likert type scale that covers 8 domains: Activities of daily living (ADL/IADL), Physical symptoms (PS), Autonomy (A), Social (SI), Psychological (PI), Spiritual issues (Sp), Financial problems (FP) and Need for information (NI). The level of statistical significance was set at 0.05.
Results
Sample consisted of 150 patients (51% men) with mean age 75.6 years old (SD = 10.1). The cancer diagnosis was 40% mostly colon cancer (38%) and for non-cancer patients hypertension (62.2%). No statistical differences were found between cancer and non cancer patients for the demographic and clinical characteristics (p > 0.05). The mean MMSE scare was 27.2 (SD = 2) in patients with cancer and 27.6 (SD = 1.9) in patients with no cancer (p = 0.313). Significantly greater scores were found on the ADL/IADL (p=.012 - p=.001), A (p=.050 - p=.002), SI (p=.007 - p=.004) and Sp (p=.014 - p=.001) in the cancer group for both problems and needs for care. Additionally, the cancer patients reported statistically significant higher need for professional care for FP (p=.022). No statistically significant differences were found for PS, PI and NI (p>.050).
Conclusions
Elderly hospitalized cancer patients have more palliative care problems and needs for care at daily living, social, spiritual and financial issues than those with no cancer. Hence, nurses should focus on meeting these needs, based on the principles of PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract